GSK says blood cancer drug meets primary goal in late-stage trial

1 year ago 35

British drugmaker GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment, had met its primary goal of progression free survival in a late-stage trial.

1. Homepage
2. category-label-
3. GSK says blood cancer drug meets primary goal in late-stage trial